Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00565760 · ClinicalTrials.gov registry record · Phase 3
Extension Study to Evaluate the Safety of Q8003 in Patients With Acute Moderate to Severe Pain
A Phase 3 study, sponsored by QRxPharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
NCT00565760 is a Phase 3 study that has completed, run by QRxPharma. The registered enrollment target is 16 participants.
The verdict
NCT00565760, a Phase 3 study, has completed, sponsored by QRxPharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a Phase 3 double-blind, multiple dose safety extension study of Q8003 administered at daily doses up to 36 mg morphine/24 mg oxycodone (Q8003 36mg/24mg) over a treatment period of up to 4 weeks. Patients with acute moderate to severe pain who have completed participation in one of the designated QRxPharma, Inc. acute pain lead-in studies will be eligible for this trial.
Interventions
- DRUG Placebo
- DRUG Q8003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00565760
The ClinicalTrials.gov registry entry for NCT00565760 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is QRxPharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00565760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00565760 about?
NCT00565760 is a clinical study titled "Extension Study to Evaluate the Safety of Q8003 in Patients With Acute Moderate to Severe Pain". This is a Phase 3 double-blind, multiple dose safety extension study of Q8003 administered at daily doses up to 36 mg morphine/24 mg oxycodone (Q8003 36mg/24mg) over a treatment period of up to 4 weeks. Patients with acute moderate to severe pain who have completed participation in one of the design...
What is the current status of trial NCT00565760?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2007-11. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00565760?
The interventions under investigation include: Placebo (DRUG), Q8003 (DRUG).
Who is sponsoring clinical trial NCT00565760?
This trial is sponsored by QRxPharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.